Table 1

Baseline characteristics of the transcatheter aortic valve implantation (TAVI) and surgical aortic valve replacement (sAVR) group

ParameterTAVI (n=101)sAVR (n=22)p Value
Age (years)81±1171±120.0004
82 (IQR 77–86)73 (IQR 63–79)
Gender. female (n/%)68/67%14/63%0.93
Weight (kg)75±1770±190.3
74 (IQR 62–85)72 (IQR 65–85)
Height (cm)167±9168±100.65
167 (IQR 160–170)166 (IQR 160–173)
NYHA FC (n) (I/II/III/IV)0/19/65/171/4/17/00.033
Logistic euroSCORE (%)24.3±14.67.2±4.7<0.0001
Coronary heart disease (n/%)51/50%9/41%0.56
Previous cardiac surgery (n/%)25/25%1/5%0.07
Prior myocardial infarction (n/%)25/25%2/9%0.19
Arterial hypertension (n/%)55/54%16/73%0.18
Diabetes (n/%)22/22%3/14%0.57
Peripheral artery occlusive disease (n/%)26/26%4/18%0.64
Chronic renal insufficiency (n/%)31/31%2/9%0.07
COPD (n/%)26/26%4/18%0.64
PCWP (mm Hg)15.6±11.117.9±7.90.42
14.0 (IQR 7.7–22.2)16.0 (IQR 12.2–24.0)
PAP mean (mm Hg)28.0±11.524.4±9.50.29
25.5 (IQR 17.0–40.0)16.2 (IQR 16.2–31.0)
PAP peak (mm Hg)44.5±18.042.9±19.30.76
39.0 (IQR 30.0–59.0)38.0 (IQR 28.7–48.2)
  • Data, if appropriate, are presented as mean ± SD and median and IQR. Significant values are printed in bold.

  • COPD, chronic obstructive pulmonary disease; NYHA FC, New York Heart Association Functional Class; PAP, pulmonary artery pressure; PCWP, pulmonary capillary mean wedge pressure.